# Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

> **NCT00620633** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** WT1-sensitized T cells

## Key facts

- **NCT ID:** NCT00620633
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-08
- **Primary completion:** 2021-02-26
- **Final completion:** 2021-02-26
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00620633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00620633, "Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00620633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*